Program
calcipotriene
Also written as “LEO 90100”, “MC2-01 cream” and “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”.
Its studies are mostly in Psoriasis · Alopecia Areata, led by 10 companies.
Drug pageCalcipotriene: every studyMany companies study it; this page follows only the 37 they lead. All 70 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| LEO Pharmaits history only | 220 open or running | phase 4since Sep 15, 2005 | Sep 15, 2005 | none ahead |
| MC2 Therapeuticsits history only | 50 open or running | phase 3since Oct 9, 2017 | Oct 9, 2017 | none ahead |
| Almirallits history only | 20 open or running | phase 3since Nov 11, 2015 | Nov 11, 2015 | none ahead |
| Mayne Pharma International Ptyits history only | 20 open or running | phase 1since Mar 15, 2012 | Mar 15, 2012 | none ahead |
| Abbott | 10 open or running | phase 3since Dec 12, 2007 | Dec 12, 2007 | none ahead |
| Egymedicalpediaits history only | 10 open or running | no phasesince Jun 23, 2023 | Jun 23, 2023 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 3since Jun 6, 2010 | Jun 6, 2010 | none ahead |
| Glenmark Pharmaceuticals Ltd. Indiaits history only | 10 open or running | phase 3since Nov 1, 2017 | Nov 1, 2017 | none ahead |
| Huadong Medicineits history only | 10 open or running | phase 3since Dec 11, 2025 | Dec 11, 2025 | none ahead |
| Tolmarits history only | 10 open or running | phase 1since Apr 6, 2017 | Apr 6, 2017 | none ahead |
Also a collaborator on its studies: Bioskin.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Abbott only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 12, 2007First study: phase 3 study in PsoriasisFirst studyNCT00574249 · 730 enrolled · Austria, Belgium, Czech Republic and more
TargetBeta
“Vitamin D receptor agonist”ChEMBL 37, by rule
Other programs on VDR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Modified-release Calcifediol Capsulerule | OPKO Health | phase 3 | 10 |
Studies
The one study Abbott leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00574249Psoriasis · Austria, Belgium, Czech Republic and more | 3 | Completed | Oct 2008 | 730 |
How it is read
Names in the registry
- “LEO 90100”, 7 entries
- “MC2-01 cream”, 4 entries
- “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”, 3 entries
- “Calcipotriol plus hydrocortisone (LEO 80190)”, 2 entries
- “MC2-01 Cream”, 2 entries
Codes read as this program: P3073.
Conditions, from the studies’ own filings
- Psoriasis, 37 studies
- Alopecia Areata, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.